Resistance mechanism in chronic lymphocytic leukemia identified
Researchers at the German Cancer Research Center (DKFZ) have succeeded in identifying a resistance mechanism that often occurs in a specific targeted therapy against chronic lymphocytic leukemia (CLL). The drug ibrutinib is effective in many cases, but therapy resistance often develops during the course of treatment. In cell culture experiments and in mice, the resistance mechanism was successfully overcome using a second drug.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/resistance-mechanism-chronic-lymphocytic-leukemia-identified